TherapeuticsMD, Inc. (NYSE MKT:TXMD) announced today it
will release its third quarter 2013 financial results on Monday,
November 4, 2013 at approximately 4:00 pm EST and will host a conference
call shortly thereafter at approximately 4:30 pm EST to review the
results. The call will be hosted by Robert Finizio, Co-Founder and Chief
Executive Officer, and Dan Cartwright, Chief Financial Officer. Call in
information follows:
|
Date
|
|
November 4, 2013
|
|
|
Time
|
|
4:30 pm EST
|
|
|
Telephone access: U.S. and Canada
|
|
800-619-2686
|
|
|
Telephone access: International
|
|
303-223-4363
|
|
|
Access code
|
|
21682427
|
|
|
Live webcast
|
|
www.therapeuticsmd.com
(see Investor tab)
|
|
An audio replay will be available on-demand shortly after the completion
of the call until November 18, 2013 at 11:59 pm EST at the
aforementioned URL, or by dialing 800-633-8284 in the U.S. and Canada,
or 402-977-9140 from abroad. The access code for all callers is 21682427.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a women’s healthcare company focused on
developing and commercializing products targeted exclusively for women.
We manufacture and distribute branded and generic prescription prenatal
vitamins, as well as over-the-counter vitamins and cosmetics, under our
vitaMedMD® and BocaGreenMD™ brands. We are developing
advanced hormone therapy pharmaceutical products that fill the critical
and long-ignored need for better treatments in the hormone and women’s
health market. Our advanced hormone therapies are based on a novel
technology that enables delivery of bio-identical hormones through a
variety of dosage forms and administration routes. These bio-identical
hormone therapies match the molecular structure of the estradiol and/or
progesterone produced in the body. Current programs include the
REPLENISH trial, a Phase 3 clinical study evaluating the safety and
efficacy of our TX 12-001-HR 17ß-estradiol and progesterone combination
product candidate in reducing the symptoms of menopause. We are also
evaluating various other potential indications for our hormone
technology, including oral contraception, preterm birth, vulvar and
vaginal atrophy, and premature ovarian failure. More information is
available at the following websites: www.therapeuticsmd.com,
www.ReplenishTrial.com,
www.vitamedmd.com,
www.vitamedmdrx.com,
and www.bocagreenmd.com.
vitaMedMD® and TherapeuticsMD® are registered trademarks and
BocaGreenMD™ is a trademark of TherapeuticsMD, Inc.
Copyright Business Wire 2013